Idiopathic inflammatory myopathies: optimum immunosuppressive treatment

P.J. Zilko, Francis Mastaglia, B.A. Phillips

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)

Abstract

The idiopathic inflammatory myopathies include polymyositis and dermatomyositis, which tend to be responsive to drug therapy, and inclusion body myositis, which is often unresponsive or only partially responsive to drugs.Corticosteroids are considered the first line treatment of these disorders, and as well as being anti-inflammatory are immunosuppressive when used at dosages above prednisolone 20 mg/day or equivalent. In those patients who are refractory to corticosteroids, or are prone to develop complications from corticosteroids, second line drugs such as methotrexate, azathioprine or intravenous immunoglobulin should be introduced. These therapies tend to be slow acting, but response often occurs in 4 to 6 weeks and allows the dosage of corticosteroid to be reduced more rapidly.In these occasional patients with inflammatory myopathies that are refractory to corticosteroids and second line agents, one should consider adding in a third line agent such as cyclosporin, chlorambucil or cyclophosphamide. Although most clinicians would use these immunosuppressive drugs singly in combination with corticosteroids, multiple drug therapy should be considered in severe refractory cases.
Original languageEnglish
Pages (from-to)262-272
JournalBiodrugs
Volume7
Issue number4
DOIs
Publication statusPublished - 1997

Fingerprint

Dive into the research topics of 'Idiopathic inflammatory myopathies: optimum immunosuppressive treatment'. Together they form a unique fingerprint.

Cite this